Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $64.44 -3.56%
Revenue Growth %: -77.2%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: -77.2%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.01 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Small stocks still very cheap vs. large - BofA
- Deutsche Bank (DB) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
